Pamrevlumab
| Monoclonal antibody | |
|---|---|
| Type | ? |
| Source | Human |
| Target | CTGF |
| Clinical data | |
| Other names | FG-3019 |
| ATC code |
|
| Identifiers | |
| CAS Number | |
| ChemSpider |
|
| UNII | |
| KEGG | |
| Chemical and physical data | |
| Formula | C6492H10018N1718O2086S48 |
| Molar mass | 147050.38 g·mol−1 |
Pamrevlumab (INN;[1] development code FG-3019) is a humanized monoclonal antibody designed for the treatment of idiopathic pulmonary fibrosis and pancreatic cancer. It binds to the connective tissue growth factor (CTGF) protein.[2]
This drug was developed by FibroGen, Inc.[3]
References
[edit]- ^ World Health Organization (2015). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 113" (PDF). WHO Drug Information. 29 (2).
- ^ Sgalla G, Franciosa C, Simonetti J, Richeldi L (August 2020). "Pamrevlumab for the treatment of idiopathic pulmonary fibrosis". Expert Opinion on Investigational Drugs. 29 (8): 771–777. doi:10.1080/13543784.2020.1773790. PMID 32447983. S2CID 218873298.
- ^ Statement On A Nonproprietary Name Adopted By The USAN Council - Pamrevlumab, American Medical Association.
 | This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it. |